Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis
复制标题
DOI：
10.1160/th13-03-0243
复制
发表时间：
2013-10-01
影响因子：
6.7
通讯作者：
Cano, Stefan J.
中科院分区：
文献类型：
--
作者：
Bamber, Luke;Wang, Maria Y.;Cano, Stefan J.
利伐沙班是一种口服的直接凝血因子Xa抑制剂，已被批准用于治疗深静脉血栓形成(DVT)和肺栓塞(PE)，并作为一种固定剂量的单一药物方案防止DVT和PE复发，不需要初始肝素化、常规凝血监测或剂量调整。这项研究评估了患者在爱因斯坦DVT中报告的治疗满意度，这是一项大型、开放标签的随机研究，比较了利伐沙班和依诺肝素/维生素K拮抗剂(VKA)治疗没有PE的急性症状性DVT患者的疗效。作为爱因斯坦深静脉血栓治疗的一部分，7个国家的1472名患者被要求完成一项新的、经过验证的治疗满意度衡量标准--在治疗12个月期间按计划到访的抗凝血治疗量表(ACTS)。在意向治疗人群中，比较研究组之间的ACTS评分。与依诺肝素/VKA组相比，利伐沙班组患者报告的满意度更高，平均ACTS评分也更高。平均行为负担得分为55.2分对52.6分(p
Rivaroxaban, an oral, direct factor Xa inhibitor, has been approved for the treatment of deep-vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE as a fixed-dose, single-drug regimen that does not require initial heparinisation, routine coagulation monitoring or dose adjustment. This study evaluated patient-reported treatment satisfaction in EINSTEIN DVT - a large, open-label, randomised study that compared rivaroxaban with enoxaparin/vitamin K antagonist (VKA) therapy in patients with acute symptomatic DVT without PE. As part of EINSTEIN DVT a total of 1,472 patients in seven countries were asked to complete a new, validated measure of treatment satisfaction - the Anti-Clot Treatment Scale (ACTS) at scheduled visits throughout 12 months of treatment. ACTS scores were compared between study groups in the intention-to-treat population. Patients reported greater satisfaction in the rivaroxaban group compared with the enoxaparin/VKA group, with higher mean ACTS scores across visits. Mean ACTS Burdens scores were 55.2 vs 52.6 (p